Q-omics provides the consensus-scored MTRNR2L8 profile across patient tissues and cancer cell-line models. MTRNR2L8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L8 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MTRNR2L8 RNA expression shows 15,864 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BRCA as cancer lineages where MTRNR2L8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L8 survival associations across molecular data types. MTRNR2L8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L8 RNA expression–survival associations across cancer types. High MTRNR2L8 expression shows unfavorable associations in UCS, BRCA, LUAD and CHOL, but favorable associations in ACC and READ. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTRNR2L8 RNA expression.
This table summarizes MTRNR2L8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L8 shows lower tumor expression in BRCA, COAD and KIRC and higher tumor expression in KICH. The BRCA box plot shows higher MTRNR2L8 RNA expression in normal versus tumor tissue (log2 FC = −0.419, t-test p < 0.001).
This table shows molecular features associated with MTRNR2L8 in patient tissues and cancer cell lines. In patient samples, MTRNR2L8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRNR2L8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
